GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast AS (LTS:0QBO) » Definitions » ROE %

Coloplast AS (LTS:0QBO) ROE % : 30.50% (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Coloplast AS ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Coloplast AS's annualized net income for the quarter that ended in Sep. 2024 was kr5,256 Mil. Coloplast AS's average Total Stockholders Equity over the quarter that ended in Sep. 2024 was kr17,233 Mil. Therefore, Coloplast AS's annualized ROE % for the quarter that ended in Sep. 2024 was 30.50%.

The historical rank and industry rank for Coloplast AS's ROE % or its related term are showing as below:

LTS:0QBO' s ROE % Range Over the Past 10 Years
Min: 16.36   Med: 58.37   Max: 68.91
Current: 30.4

During the past 13 years, Coloplast AS's highest ROE % was 68.91%. The lowest was 16.36%. And the median was 58.37%.

LTS:0QBO's ROE % is ranked better than
97.51% of 802 companies
in the Medical Devices & Instruments industry
Industry Median: -0.21 vs LTS:0QBO: 30.40

Coloplast AS ROE % Historical Data

The historical data trend for Coloplast AS's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast AS ROE % Chart

Coloplast AS Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.62 61.96 57.18 37.38 28.67

Coloplast AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.33 29.90 31.97 31.15 30.50

Competitive Comparison of Coloplast AS's ROE %

For the Medical Instruments & Supplies subindustry, Coloplast AS's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coloplast AS's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's ROE % distribution charts can be found below:

* The bar in red indicates where Coloplast AS's ROE % falls into.



Coloplast AS ROE % Calculation

Coloplast AS's annualized ROE % for the fiscal year that ended in Sep. 2024 is calculated as

ROE %=Net Income (A: Sep. 2024 )/( (Total Stockholders Equity (A: Sep. 2023 )+Total Stockholders Equity (A: Sep. 2024 ))/ count )
=5052/( (17299+17942)/ 2 )
=5052/17620.5
=28.67 %

Coloplast AS's annualized ROE % for the quarter that ended in Sep. 2024 is calculated as

ROE %=Net Income (Q: Sep. 2024 )/( (Total Stockholders Equity (Q: Jun. 2024 )+Total Stockholders Equity (Q: Sep. 2024 ))/ count )
=5256/( (16524+17942)/ 2 )
=5256/17233
=30.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. ROE % is displayed in the 30-year financial page.


Coloplast AS  (LTS:0QBO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=5256/17233
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(5256 / 27812)*(27812 / 48326.5)*(48326.5 / 17233)
=Net Margin %*Asset Turnover*Equity Multiplier
=18.9 %*0.5755*2.8043
=ROA %*Equity Multiplier
=10.88 %*2.8043
=30.50 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=5256/17233
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (5256 / 6412) * (6412 / 7212) * (7212 / 27812) * (27812 / 48326.5) * (48326.5 / 17233)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8197 * 0.8891 * 25.93 % * 0.5755 * 2.8043
=30.50 %

Note: The net income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Coloplast AS ROE % Related Terms

Thank you for viewing the detailed overview of Coloplast AS's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast AS Business Description

Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast AS Headlines

No Headlines